An investigation has commenced on behalf of applied therapeutics, inc. shareholders. contact levi & korsinsky to discuss your aplt losses.

New york, ny / accesswire / december 5, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of applied therapeutics, inc. ("applied therapeutics, inc.") (nasdaq:aplt) concerning possible violations of federal securities laws. applied therapeutics issued a press release on november 27, 2024, announcing "that the u.s. food and drug administration (fda) has issued a complete response letter (crl) for the new drug application (nda) for govorestat, a novel, central nervous system (cns)-penetrant aldose reductase inhibitor (ari), for the treatment of classic galactosemia.
APLT Ratings Summary
APLT Quant Ranking